China's Pharmaceutical Trade in 2023: Trends and Outlook

China's pharmaceutical industry plays a crucial role in the global market, and keeping track of its trade performance is essential for industry stakeholders. In 2023, China experienced a decline in both imports and exports of pharmaceutical products, reflecting various factors impacting the sector. This article provides an overview of China's pharmaceutical trade in 2023, highlights key trends, and offers insights into the future outlook.

A Decline in Total Trade Volume:
In 2023, China's total pharmaceutical trade volume amounted to $195.365 billion, representing an 11.11% decline compared to the previous year. The import value stood at $93.309 billion, showing a modest growth rate of 2.4%. On the other hand, the export value reached $102.056 billion, reflecting a significant decline of 20.68%. Despite the overall decline, experts anticipate a gradual stabilization and marginal growth in pharmaceutical exports during the second half of 2024.

Segment Analysis:

1. Traditional Chinese Medicine (TCM):
The export value of TCM products in 2023 was $5.461 billion, indicating a decrease of 3.32%. Among the subcategories, the highest export value was observed in plant extracts, which reached $3.259 billion, reflecting a decline of 6.54%. Additionally, exports of TCM materials and decoction pieces amounted to $1.32 billion, showing a decline of 5.85%. However, the export value of health supplements increased by 42.17%, primarily driven by a significant surge of 66.5% in fish oil products. The export value of patented Chinese medicines declined by 10.24%.

2. Western Medicine:
In 2023, the export value of Western medicine accounted for 50.04% of total pharmaceutical exports, totaling $51.071 billion, representing a decline of 20.27%. The import value reached $52.813 billion, showing a growth rate of 4.88%. Among the submarkets, the export value of Western medicine raw materials decreased by 20.66%, while Western finished drugs declined by 4.01%. However, exports of biochemical drugs experienced a significant decline of 34.97%.

3. Medical Devices:
The total import and export value of medical devices in 2023 amounted to $83.13 billion, reflecting a decline of 14.18%. The export value was $45.525 billion, showing a decline of 22.8%, while the import value reached $37.605 billion, indicating a slight decrease of 0.77%. Medical devices accounted for 44.61% of China's total pharmaceutical exports. Notably, exports of medical dressings, disposable consumables, and hospital diagnostic and therapeutic products experienced significant declines, while exports of oral equipment and materials showed positive growth.

Market Performance:

1. Belt and Road Initiative (BRI) Countries:
China's pharmaceutical trade with BRI countries in 2023 reached $52.696 billion, reflecting a decline of 10.98%. Among the subcategories, exports and imports of TCM products showed slight declines, while Western medicine and medical device exports decreased by double-digit percentages.

2. Regional Comprehensive Economic Partnership (RCEP):
China's pharmaceutical trade with RCEP countries in 2023 amounted to $36.715 billion, indicating a decline of 16.86%. The export value of TCM products showed a slight decrease, while Western medicine and medical device exports experienced significant declines.

3. European Union (EU):
China's pharmaceutical trade with the EU in 2023 reached $66.32 billion, showing a decline of 6.08%. Import value increased, while export value decreased compared to the previous year.

Outlook and Conclusion:
Despite the challenges faced by China's pharmaceutical industry in 2023, the market is expected to stabilize in the first half of 2024, with modest growth anticipated in the second half. Traditional Chinese medicine remains a significant export category, while the decline in Western medicine and medical device exports highlights areas for industry stakeholders to address. Monitoring market trends and adapting strategies will be crucial for the Chinese pharmaceutical industry to regain its momentum in the global market.